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Posttranslational Regulation of IRF-4
Activity by the Immunophilin FKBP52
(DBD). However, IRF-4 was exclusively found in B lym-
phocytes associated with PU.1, an Ets family member
involved in lymphoid and myeloid lineage development.
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Terry Fox Molecular Oncology Group The IRF-4.PU.1 heterodimer formed a transcriptional ac-
tivating complex. Independently, another group clonedLady Davis Institute for Medical Research and
Departments of Microbiology and Immunology, IRF-4 as lymphoid-specific IRF (LSIRF), which was ex-
pressed at all stages of B cell development and in matureMedicine, and Oncology
McGill University T cells. LSIRF expression was upregulated by receptor-
cross-linking stimuli such as plant lectins, CD3, or IgM.Montreal, Canada H3T 1E2
In contrast to B cells, IRF-4 in T cells was able to bind
autonomously to the ISRE of the MHC class I promoter
(Matsuyama et al., 1995). A third group isolated a humanSummary
equivalent of IRF-4 from an adult T cell leukemia (ATL)
cell line, called IFN consensus sequence-binding proteinInterferon regulatory factor-4 (IRF-4) plays an impor-
in adult T cell leukemia cell lines or activated T cellstant role in immunoregulatory gene expression in B and
(ICSAT) (Yamagata et al., 1996). The human T cell leuke-T lymphocytes and is also highly expressed in human T
mia virus-I (HTLV-I) is the etiologic agent of adult T cellcell leukemia virus type 1 infected cells. In this study,
leukemia (ATL), an aggressive and fatal leukemia ofwe characterize a novel interaction between IRF-4 and
CD41 T lymphocytes (Poiez et al., 1980; Yoshida et al.,the FK506-binding protein 52 (FKBP52), a 59 kDa
1982) and is also associated with a neurological demye-member of the immunophilin family with peptidyl-prolyl
linating disease, tropical spastic paraparesis (Gessainisomerase activity (PPIase). IRF-4-FKBP52 association
et al., 1985; Daenkes et al., 1990). The oncogenic poten-inhibited IRF4-PU.1 binding to the immunoglobulin
tial of HTLV-I resides in the 353±amino acid (aa), 40 kDalight chain enhancer El2±4 as well as IRF-4-PU.1 trans- viral Tax oncoprotein, a positive regulator of viral geneactivation, effects that were dependent on functional
transcription. ICSAT/IRF-4 was shown to be expressedPPIase activity. FKBP52 association also resulted in a
exclusively in a restricted subset of lymphocytes: onlystructural modification of IRF-4, detectable by immu-
T cells treated with phorbol myristate acetate (PMA)noblot analysis and by IRF-4 partial proteolysis. These
or infected with HTLV-1 produced IRF-4. Jurkat cellsresults demonstrate a novel posttranslational mecha-
transiently transfected with the HTLV-1 tax gene alsonism of transcriptional control, mediated through the
expressed IRF-4, indicating that Tax may function as aninteraction of an immunophilin with a transcriptional
indirect activator of the IRF-4 promoter (Yamagata etregulator.
al., 1996). IRF-4 (Pip/LSIRF/ICSAT) is structurally similar
to another member of the IRF family, IRF-8 (formerly
Introduction called ICSBP), and expression is not inducible by IFN.
However, human IRF-4 possessed a very different func-
The interferon regulatory factors (IRFs) are a family of tion compared to its murine counterpart; while IRF-4-
transcription factors involved in the early host response PU.1 functioned as a transactivator complex, ICSAT
to pathogens, immunomodulation, and hematopoietic exerted an IRF-2 and ICSBP-like repressive effect on
development (Nguyen et al., 1997; Stark et al., 1998; IFN- and IRF-1-induced gene activation.
Mamane et al., 1999). The best characterized members In this paper, a novel physical and functional inter-
of this family, IRF-1 and IRF-2, were originally identified action between IRF-4 and FK506-binding protein 52
through studies on the transcriptional regulation of the (FKBP52), an immunophilin with peptidyl-prolyl iso-
human IFNb gene (Fujita et al., 1988; Miyamoto et al., merase (PPIase) and chaperone-like activities, has been
1988). This family now includes seven additional mem- characterized. FKBP52 inhibited IRF-4 DNA binding and
bers: IRF-3 through IRF-9 (Mamane et al., 1999), as well transactivation functions by a posttranslational modifi-
as virally encoded IRF homologs in the human herpes cation of IRF-4 that was dependent on the PPIase activ-
virus 8 (HHV-8) genome (Moore et al., 1996; Burysek et ity of FKBP52. These results suggest that FKBP52 in-
al., 1999). Structurally, all IRF family members share a duces a conformational change in IRF-4 by cis-trans
tryptophan repeat motif in the N-terminal DNA-binding prolyl isomerization that interferes with IRF-4 DNA bind-
domain and homology with the Myb oncoproteins. ing and transcriptional activity, thus demonstrating a
One of the recently discovered members of the IRF novel posttranslational mechanism controlling gene
family, IRF-4, was cloned from three independent transcription.
sources. First cloned as PU.1 interacting partner (Pip),
which binds to the murine immunoglobulin (Ig) light Results
chain enhancer El2±4 (Eisenbeis et al., 1993, 1995), IRF-4
possesses an IRF-like N-terminal DNA-binding domain In Vivo Interaction of IRF-4 and FKBP52
To identify potential partners of IRF-4, a yeast two-hybrid
analysis was performed; since full-length IRF-4 pos-* To whom correspondence should be addressed (e-mail: mijh@
musica.mcgill.ca). sessed intrinsic transcriptional activity, the bait utilized
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Figure 1. Interactions between IRF-4 and FKBP52
(A) Schematic representation of FKBP52. FKBP52 possesses three functional domains (brackets): FKBP-like domain 1 with the PPIase activity
(aa 1±148), FKBP-like domain 2 with an ATP/GTP binding site (aa 148±267), and three tetratricopeptide repeats (aa 267±389), which mediate
protein±protein interactions.
(B±D) The proline-rich region of IRF-4 (aa 150±237) interacts with the tetratricopeptide repeats of FKBP52 (aa 233±459). COS-7 cells were
transfected with Myc-tagged FKBP52 and FLAG- or HA-tagged IRF-4 constructs (15 mg each), and whole-cell extracts (WCE) (300 mg) were
FKBP52 Inhibits IRF-4 Transcriptional Activity
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was IRF-4 aa 150±410 comprising a proline-rich domain this domain alone was not stably expressed as a tagged
peptide and therefore was not tested directly, hence theand the C-terminal IRF association domain (IAD). Among
the 106 clones screened, 10 clones were positive for parentheses in Figure 1E (Y. M., unpublished data).
Interestingly, with the inclusion of additional C-termi-mating and were subsequently sequenced for identifica-
tion. Two of these clones corresponded to full-length nal amino acids beyond aa 410, FKBP52 did not associ-
ate with IRF-4 (aa 1±439), IRF-4 (aa 1±419) (Figure 1D,cDNA of the human immunophilin FKBP52, a member
of the immunophilin family of proteins with peptidyl- lanes 2 and 4), or with full-length IRF-4 (Y. M., unpub-
lished data); similarly, IRF-4 did not interact with theprolyl isomerase (PPIase) activity and chaperone-like
functions (Czar et al., 1994; Radanyi et al., 1994; Perrot- N- or C-terminal parts of FKBP52 (Y. M., unpublished
data). The conformation of IRF-4 may be inaccessible toApplanat et al., 1995). FKBP52 contains three ªFKBP-
likeº domains: domain 1 possesses features required FKBP52 because of structural constraints imposed by
the C-terminal autoinhibition element, which folds backfor PPIase activity and FK506 binding, domain 2 con-
tains GTP- and ATP-binding sites, and domain 3 con- on the N-terminal DNA-binding domain (Eisenbeis et al.,
1995; Brass et al., 1996, 1999).tains the tetratricopeptide repeats (TPR) that are respon-
sible for the association with HSP90 (Figure 1A) (Radanyi
et al., 1994; Kay, 1996).
In Vivo Interaction between IRF-4 and FKBP52
To determine which domain of FKBP52 interacted
in HTLV-1-Transformed Cells and in B Cells
with IRF-4, FKBP52 was truncated to an N-terminal frag-
IRF-4 has been previously shown to be expressed in all
ment (N-FKBP52 [aa 1±243]) containing domains 1 and
Tax-expressing HTLV-I-transformed cells as well as in
2 and a C-terminal fragment (DN-FKBP52 [aa 233±459])
B cells (Eisenbeis et al., 1995; Matsuyama et al., 1995;
containing the TPR domains, and both forms were sub-
Brass et al., 1996; Yamagata et al., 1996). To investigate
cloned into a Myc-tagged vector. In order to confirm
IRF-4-FKBP52 interactions, three HTLV-I-transformed T
the interaction between FKBP52 and IRF-4, Myc-tagged
cell lines, C8166, MT-2, and MT-4; one HTLV-II-trans-
forms of FKBP52 and FLAG-tagged IRF-4 (aa 150±410)
formed T cell line MO-T; and five B lymphoid cell lines
were cotransfected into COS-7 cells. After immunopre-
were examined. C8166, MT-2, and MO-T expressed high
cipitation of Myc-FKBP52 from cell extracts with anti-
amounts of IRF-4 whereas MT-4, which does not ex-
Myc antibody, immunoblot analysis using a-FLAG anti-
press Tax (Jeang et al., 1997), contained no IRF-4 (Figure
body revealed that IRF-4 (aa 150±410) coprecipitated
2A, upper panel, lanes 1±3). The levels of FKBP52 were
with full-length FKBP52 (Figure 1B, lane 2) as well as
approximately equal in all the T cell lines (Figure 2A,
the C-terminal fragment (Figure 1B, lane 4) but did not
lower panel). Coprecipitation assays using an a-FKBP52
coimmunoprecipitate with the N-terminal 1±243 aa frag-
antibody revealed that endogenous IRF-4 interacted
ment (Figure 1B, lane 6), indicating TPR-mediated pro-
with endogenous FKBP52 in C8166, MT-2, and MO-T
tein±protein interactions between FKBP52 and IRF-4.
but not in the MT-4 cell line (Figure 2A, middle panel,
The lower panel of Figure 1B revealed that Myc-tagged
lanes 1±3). This interaction was also examined in B cells:
forms of FKBP52 were expressed and immunoprecipi-
two murine cell lines, A20 and 70Z/3; and three human
tated with anti-Myc antibody.
cell lines, KR-12, MC/CAR, and Namalwa cells. Variable
amounts of IRF-4 and PU.1 were detected in all B cell
Mapping the IRF-4 Interaction Domains
lines (Figure 2B, upper panel, lanes 1±5) but not in Jurkat
To localize the region of IRF-4 interacting with the im-
T cells (Figure 2B, upper panel, lane 6). IRF-4-FKBP52
munophilin, deletion mutants of IRF4 and full-length
interaction was detected in all B cells examined but not
FKBP52 were cotransfected into COS-7 cells and ana-
in Jurkat T cells (Figure 2B, middle panel). The amount
lyzed by coimmunoprecipitation. FKBP52 coprecipi-
of IRF-4 interacting with FKBP52 did vary amongst the
tated with IRF-4 (aa 1±410), IRF-4 (aa 1±340), IRF-4 (aa
cell lines, possibly due to differences in IRF-4 expression
1±237), IRF-4 (aa 150±340), and IRF-4 (aa 150±410) (Fig-
level in the different cell types.
ure 1C, lanes 2, 4, 6, 9, and 11), indicating that the
interaction domain of IRF-4 was located within the
N-terminal 237 aa. FKBP52 did not coprecipitate with FKBP52 Inhibits IRF-4 Interaction with PU.1
and Subsequent Binding to the lB ElementIRF-4 (aa 1±150) (Figure 1D, lane 8) or with IRF-4 con-
taining the internal deletion aa D150±340 (Figure 1D, IRF-4 was originally cloned as a murine transcription
factor recruited to composite elements within the immu-lane 6). The results of the domain interaction studies
are summarized schematically in Figure 1E. Based on noglobulin light chain gene enhancer El2±4 through spe-
cific interaction with PU.1, an Ets family member (Eisen-these results, the proline-rich region of IRF-4 (aa 150±
237) appears to be the minimal region required for beis et al., 1993). We therefore investigated the effect
of FKBP52 on the formation of the IRF-4-PU.1 complex.FKBP52 interaction. However, despite repeated efforts,
immunoprecipitated (IP) with anti-Myc antibody 9E10 (amyc). Immunoprecipitated complexes were run on a 15% SDS-PAGE and immunoblotted
(IB) with anti-FLAG antibody to detect FLAG-IRF-4 expression (upper panels, [B and C]), anti-HA antibody for IRF-4 (upper panel, [D]). The
membranes were reprobed with amyc to verify protein expression and successful IP (lower panels, [B±D]). WCE (30 mg) were used as input,
and extract from untransfected COS-7 cells (300 mg) was immunoprecipitated with amyc as control IP.
(E) Schematic summary of the IRF-4 interaction domains with full-length FKBP52. The 150±237 aa construct could not be stably expressed
as a tagged peptide and therefore was not tested directly, hence the parentheses in Figure 1E. The different domains of IRF-4 are illustrated:
DNA-binding domain with the tryptophan repeats seen in all IRF members (DBD; aa 1±150), the proline-rich region (Pro; aa 150±237), the IRF
association domain (IAD; aa 237±410), and the C-terminal autoinhibition element (AIE; aa 410±450).
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Figure 2. Coimmunoprecipitation Demonstrates Interaction between FKBP52 and Endogenous IRF-4 in HTLV-I-Transformed T Cells and B
Cells
(A) C8166, MT2, MT4, and MO-T WCE (500 mg) were immunoprecipitated with an a-FKBP52 antibody, and complexes were run on 10% SDS-
PAGE and immunoblotted using a-IRF-4 antibody (middle panel) and a-FKBP52 antibody (lower panel). Input extracts consisted of 50 mg of
WCE (upper panel). The control IP was performed by incubating WCE (500 mg) with normal precleared mouse serum (data not shown).
(B) A20, KR-12, MC/CAR, 70Z/3, Namalwa, and Jurkat WCE (500 mg) were immunoprecipitated with an a-FKBP52 antibody, and complexes
were run on 10% SDS-PAGE and immunoblotted using a-IRF-4 antibody (second panel) and a-FKBP52 antibody (fourth panel). Input extracts
consisted of 50 mg WCE (first and third panels). The control IP was performed by incubating WCE (500 mg) with normal precleared mouse
serum (data not shown).
Nuclear extracts from COS-7 cells transfected with concentration of immunosuppressant was previously
shown to abolish all PPIase activity (Pahl and Keller,IRF-4 and PU.1 were analyzed by EMSA using the lB
element, which includes partially overlapping binding 1992; Peattie et al., 1992; Leverson and Ness, 1998) but
had no effect on IRF-4 or PU.1 binding in the absencesites for IRF-4 and PU.1 (Eisenbeis et al., 1995; Brass
et al., 1996, 1999). As previously shown, IRF-4 alone did of FKBP52 (Y. M., unpublished data). This result indi-
cated that formation of the ternary complex (IRF-4-PU.1-not bind to the lB element (Figure 3A, lane 1); FKBP52
likewise did not have intrinsic DNA binding activity (Fig- DNA) was inhibited due to the sequestration of IRF-4
by FKBP52. Likewise, ascomycin had no effect on IRF-ure 3A, lane 2). In contrast, the PU.1-DNA complex was
detected in the absence of IRF-4 (Figure 3A, lane 4) and 4-FKBP52 immunoprecipitations when incubated with
cell extracts from the cell lines described in Figure 2the complex was shifted with anti-PU.1 antibody (Figure
3A, lane 3). Addition of FKBP52 to the PU.1-containing (Y. M., unpublished data).
extracts for different times did not affect the PU.1 DNA
complex (Figure 3A, lanes 5±8). Nuclear extracts from FKBP52 Peptidyl-Prolyl Isomerase Activity Is Required
for Inhibition of IRF-4 DNA Bindingcells transfected with both IRF-4 and PU.1 expression
plasmids were also incubated with the lB element and To examine the effect of FKBP52 on IRF-4 DNA binding,
recombinant IRF-4 and extracts from C8166 cells weretwo complexes were identifiedÐthe PU.1 specific com-
plex as well as a slower migrating complex containing analyzed by EMSA using the ISRE element of ISG-15.
Complexes were detected using the ISRE probe withboth PU.1 and IRF-4 (Figures 3A, lane 11, and 3B, lane
3) as determined by supershift analysis with anti-PU.1 recombinant IRF-4 or C8166 nuclear extracts incubated
for different times (Figures 3C, lanes 1±4, and 3D, lanesand anti-IRF-4 antibody (Figure 3A, lanes 9 and 10, re-
spectively). FKBP52 had no effect on PU.1-DNA binding 2±5, respectively). Although one complex was seen with
recombinant IRF-4 (Figure 3C, lanes 1±4), two com-(Figure 3A, lanes 5±8) but blocked IRF-4 binding to the
lB element (Figures 3A, lanes 12±15, and 3B, lanes 4±7). plexes were detected with C8166 nuclear extracts (Fig-
ure 3D, lanes 2±5). The presence of IRF-4 in bothTo determine if functional PPIase activity was required
for FKBP52 inhibition of IRF-4-PU.1 DNA binding, asco- complexes was confirmed by supershift analysis with
anti-IRF-4 antibody (Figure 3D, lane 1). Recombinant IRF-4mycin (an ethyl analog of FK506, an immunosuppressant
that inhibits PPIase activity) was incubated with cell or C8166 extracts were also incubated with the ISRE
probe in the presence of GST-FKBP52 (Figures 3C, lanesextracts for different times. The presence of as little as
10 mM ascomycin in the DNA binding assay restored 5±8, and 3D, lanes 6±9); although FKBP52 itself did not
form a complex (Figures 3C, lane 13, and 3D, lane 14),IRF-4-PU.1 binding to the lB probe (Figure 3B, lanes
8±11), whereas DMSO (used to dilute the drug) had no it prevented IRF-4 from binding to DNA (Figures 3C,
lanes 5±8, and 3D, lanes 6±9, respectively). To determineeffect on IRF-4 binding (Y. M., unpublished data). This
FKBP52 Inhibits IRF-4 Transcriptional Activity
133
Figure 3. FKBP52 Inhibits IRF-4 DNA Binding Activity
(A) Nuclear extracts were collected from COS-7 cells transfected with IRF-4, PU.1, or both IRF-4 and PU.1 expression plasmids (10 mg each).
EMSA was performed using 3 mg nuclear extracts incubated with the 32P-labeled probe corresponding to the lB element (Eisenbeis et al.,
1995; Brass et al., 1996). PU.1 nuclear extracts were incubated with GST-FKBP52 for increasing times at 258C (lanes 5±8). The complex (lower
arrowhead) contained PU.1 as determined by supershift analysis (P, lane 3). IRF-4-PU.1 nuclear extracts were also incubated with GST-
FKBP52 (lanes 12±15). The two complexes (arrowheads) contained IRF-4 and PU.1 as seen by supershifting with a-PU.1 (P; lane 9) and
a-IRF-4 (I; lane 10). As controls, IRF-4 nuclear extracts and GST-FKBP52 were incubated with the lB probe (lanes 1 and 2, respectively).
(B) Nuclear extracts were collected from COS-7 cells transfected with IRF-4 and PU.1 (10 mg each). EMSA was performed as described in
(A). The two complexes (arrowheads) contained IRF-4 and PU.1 as seen by the supershift with a-IRF-4 (I; lane 1) and a-PU.1 (P; lane 2).
IRF-4-PU.1 nuclear extracts were incubated with GST-FKBP52 (lanes 4±11) and in the presence of 10 mM of ascomycin (lanes 8±11).
(C) EMSA was performed using His-tagged IRF-4 (100 ng) and GST-FKBP52 (200 ng). The 32P-labeled probe corresponded to the ISRE of the
ISG15 gene. Recombinant IRF-4 was incubated in the absence (lanes 1±4) or presence of FKBP52 (lanes 5±12) for increasing times at 258C.
Recombinant IRF-4 and FKBP52 were also incubated in the presence of 10 mM of ascomycin (lanes 9±12). The control consisted of FKBP52
incubated with the ISG15 probe (lane 13). The arrowhead indicates the IRF-4-ISG15 complex.
(D) Using C8166 nuclear extracts (3 mg) with the ISRE probe, two complexes were detected (arrowheads). Supershift analysis using an a-IRF-4
antibody demonstrated the presence of IRF-4 in both complexes (lane 1). C8166 extracts were incubated in the absence (lanes 2±5) and in




Figure 4. Analysis of IRF-4 Transactivation Potential in the Presence of FKBP52
(A) COS-7 cells were transfected with 2 mg of each of the B4TK-CAT reporter (Eisenbeis et al., 1995; Brass et al., 1996) and the IRF-4 and/
or PU.1 expressing plasmids, as well as increasing amounts of FKBP52 expressing plasmid (2, 5, 10, 15, 20, and 25 mg).
(B) COS-7 cells were transfected as described in (A) and were treated with 2 mM of ascomycin for 16 hr.
(C) COS-7 cells were transfected with 2 mg of each of the B4TK-CAT reporter and IRF-4 or PU.1 expressing plasmids, as well as increasing
amounts of DN-FKBP52 (aa 233±459) expressing plasmid (2, 5, 10, 15, 20, and 25 mg).
(D) COS-7 cells were transfected with 2 mg of each of the PRDII-CAT reporter and the NF-kB p65 expressing plasmid, as well as increasing
amounts of FKBP52 expressing plasmid (2, 5, 10, 15, 20, and 25 mg). CAT activity was analyzed 48 hr posttransfection using 10 mg WCE for
4 hr at 378C. CAT activity values correspond to an average of three to six independent experiments and were normalized to bGal expression.
if functional PPIase activity was required for FKBP52 FKBP52 Inhibits IRF-4 Transactivation
Previously, the IRF-4-PU.1 dimer was shown to stimu-inhibition of IRF-4 binding, recombinant IRF-4 or C8166
nuclear extracts were incubated with recombinant late the transcriptional activity of the El2±4 lB element
in a synergistic manner (Eisenbeis et al., 1995; Brass etFKBP52 and ascomycin (10 mM) for different times (Fig-
ures 3C, lanes 9±12, and 3D, lanes 10±13); again, the al., 1996). The ability of FKBP52 to interfere with IRF-4
and IRF-4-PU.1 transactivation was next investigatedpresence of ascomycin in the DNA binding assay mix
restored IRF-4 binding to the ISRE probe. The nature using COS-7 cells transfected with IRF-4, PU.1, and
increasing amounts of FKBP52 expression plasmid. Us-of the upper IRF-4 complex, which is not restored by
ascomycin, is not clear (Figure 3D, lanes 2±5). This com- ing the B4TK-CAT construct with a tetramer of the El2±4
lB element driving the CAT reporter, a greater than 7- toplex may represent an IRF-4 dimer, IRF-4 and an uniden-
tified host cellular protein, or a complex that is irrevers- 8-fold transactivation was produced by the synergistic
combination of IRF-4 and PU.1 (Figure 4A, lane 5), whileibly inhibited by FKBP52.
FKBP52 Inhibits IRF-4 Transcriptional Activity
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Figure 5. FKBP52 Induces a Conformational Change in IRF-4 and Protects from Proteolytic Degradation
(A) Recombinant His-tagged IRF-4 (100 ng) was incubated with GST-FKBP52 (200 ng) at 258C and 378C for different times. IRF-4 alone (lane
1, upper panel) was incubated at 378C for 1 hr as control. The same experiment was repeated in the presence of 10 mM of ascomycin (lower
panel). The control consisted of IRF-4 and 10 mM of ascomycin incubated at 378C for 1 hr (lane 1, lower panel). Samples were run on 8%
SDS-PAGE, transferred to a membrane, and immunoblotted with anti-IRF-4 antibody.
(B) In vitro translated 35S-labeled His-IRF-4 (1 ml) was preincubated with BSA (200 ng, lanes 1±8), GST-FKBP52 (200 ng, lanes 9±24), or GST-
FKBP52 and ascomycin (1 mM, lanes 17±24) for 1 hr at 258C; IRF-4, IRF-4/FKBP52, and IRF-4/FKBP52/ascomycin reactions were subjected
to chymotrypsin digestion (2 ng per reaction) for different times at 258C. Digestion reactions were terminated by the addition of 1X SDS sample
loading buffer, loaded on 15% SDS-PAGE, and visualized by autoradiograghy. Controls (lanes 1 and 9) were incubated for 30 min at 258C in
the absence of chymotrypsin.
IRF-4 or PU.1 alone did not possess a strong transacti- unpublished data). Inhibition of IRF-4 was also IRF-4
specific, based on the observation that increasingvation potential (Figure 4A, lanes 2 and 3, respectively).
FKBP52 itself had no effect on the B4TK-CAT (Figure FKBP52 did not affect NF-kB p65-mediated transactiva-
tion of an NF-kB-containing CAT reporter plasmid (Fig-4A, lane 4), whereas increasing amounts of FKBP52 in
the presence of IRF-4 and PU.1 resulted in a dramatic ure 4D, lanes 4±9).
decrease in IRF-4-PU.1 transactivation capacity (Figure
4A, lanes 6±11). Next, transfected cells were incubated FKBP52 Induces a Conformational Change in IRF-4
Analysis of the expression pattern of IRF-4 in extractswith ascomycin (2 mM) for 16 hr; ascomycin completely
blocked the inhibition of IRF-4-PU.1 transactivation by from HTLV-1-infected cells revealed two closely migrat-
ing bands corresponding to IRF-4. The slower migratingFKBP52 (Figure 4B, lanes 6±11), whereas the drug had
no effect on IRF-4-PU.1 transactivation in the absence of form of IRF-4 did not appear to correspond to phosphor-
ylated IRF-4, since calf intestinal phosphatase treatmentFKBP52 (Figure 4B, lane 5). Similar results were obtained
when a truncated FKBP52 lacking the PPIase domain did not affect IRF-4 migration (Y. M., unpublished data).
To examine the relationship between the PPIase activity(DN-FKBP52) was cotransfected in increasing amounts;
no decrease in transactivation potential was observed of FKBP52 and the distinct IRF-4 forms observed on
SDS-PAGE, recombinant IRF-4 and FKBP52 were incu-(Figure 4C, lanes 6±11). Using a different reporter con-
struct, IRF-4 produced a moderate increase in ISG-15- bated at 258C and 378C for different times; recombinant
IRF-4 alone was detected as a unique form by immu-CAT activity (2- to 3-fold) (Y. M., unpublished data).
Although FKBP52 itself had no effect on reporter gene noblot (I) (Figure 5A, lane 1). When incubated with
FKBP52, a second band (II) with a slightly faster migra-activity, increasing amounts of FKBP52 also produced
a concentration-dependent inhibition of IRF-4 transacti- tion accumulated with time (Figure 5A, lanes 2±9). The
appearance of the faster migrating form was observedvation. FKBP52-mediated inhibition also required func-
tional PPIase activity, since the use of ascomycin and as early as 5 min (Figure 5A, lanes 2 and 3), and by
45 min IRF-4 was completely converted into the fasterDN-FKBP52 cotransfection restored IRF-4 activity (Y. M.,
Immunity
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migrating form (Figure 5A, lanes 10 and 11). This effect
was specific to FKBP52, since IRF-4 alone remained
as a single form (Figure 5A, lane 1; data not shown).
Furthermore, the appearance of the faster migrating
form was completely inhibited in the presence of the
PPIase inhibitor ascomycin (Figure 5A, lower panel,
lanes 2±11). Thus, the appearance of the faster migrating
form is dependent on functional PPIase activity of
FKBP52.
To further confirm the conformational alteration in
IRF-4, partial proteolytic digestion of recombinant IRF-4
was performed in the presence or absence of recombi-
nant FKBP52 and ascomycin (Figure 5B, lanes 2±8, lanes
10±16, and lanes 18±24). Partial proteolytic cleavage Figure 6. Ascomycin Induces IgLl mRNA Expression in the Pre-B
of 35S-labeled IRF-4 by chymotrypsin was blocked by Cell Line 70Z/3
preincubation of IRF-4 with FKBP52 for 1 hr (Figure 5B, Three cell lines, A20, 70Z/3, and Jurkat T cells (1 3 107 cells each),
lanes 10±16). Strikingly, the presence of 10 mM asco- were treated with ascomycin (2 mM) for different times. Total RNA
was extracted from these cells and RT±PCR was performed on 2mycin restored the partial proteolytic digest pattern and
mg RNA using labeled IgLl (top panel), GAPDH (middle panel), andconfirmed the importance of the PPIase activity of
IRF-4 (bottom panel) specific primers. Due to high IgLl expressionFKBP52 in mediating proteolysis-resistant conformation
in A20, the room temperature reaction was diluted 100-fold for theof IRF-4 (Figure 5B, lanes 18±24). Ascomycin had no PCR reaction. The room temperature reaction was also diluted 100-
effect on the proteolytic digest of IRF-4 alone, and simi- fold and 10-fold for GAPDH and IRF-4 amplification, respectively.
lar results were obtained with trypsin proteolysis (Y. M., Cells not treated with ascomycin were incubated with DMSO (used
to dilute the drug) for 72 hr.unpublished data).
Ascomycin Induces the Expression of IgLl DNA binding required functional peptidyl-prolyl isom-
in the Murine Pre-B Cell Line 70Z/3 erase (PPIase) activity of FKBP52, since the PPIase in-
70Z/3, a mouse pre-B lymphoma cell line, has been hibitor ascomycin restored IRF-4 binding. Transactiva-
used extensively as a model to study the transcriptional tion by IRF-4-PU.1 and IRF-4 was also abrogated by
regulation of immunoglobulin genes (Paige et al., 1981; FKBP52 in a concentration-dependent manner, an effect
Koromilas et al., 1995). 70Z/3 expresses both IRF-4 and that also required functional PPIase activity, since both
PU.1 at levels similar to those in differentiated B cells ascomycin and a mutant of FKBP52 (DN-FKBP52) lack-
(Figure 2B, lanes 1±5; data not shown) but does not ing PPIase activity blocked the inhibitory effect. Incuba-
express surface immunoglobulins. Furthermore, the tion with FKBP52 led to the appearance of a faster mi-
PU.1/IRF-4 complex does not stimulate IgLl mRNA pro- grating IRF-4 band as visualized by immunoblot analysis
duction in these cells. To determine if the PPIase activity and by partial proteolysis of IRF-4. Finally, incubation
of FKBP52 was responsible for the absence of IRF-4/ of the pre-B cell line 70Z/3 with ascomycin resulted in
PU.1 activity, the pre-B cell line 70Z/3 was treated with the expression of IgLl, an IRF-4-PU.1-regulated gene
ascomycin (2 mM) for 0±72 hr. Using an RT±PCR-based in B cells. Based on these observations, we conclude
assay, IgLl expression was detected at 48 and 72 hr that FKBP52 alters the conformation of IRF-4 by cis-
after ascomycin treatment (Figure 6, upper panel, lanes trans isomerization of proline residues; such a modifica-
7 and 8); IgLl mRNA expression was also detected at tion appears to convert IRF-4 from a configuration capa-
36 hr (Y. M., data not shown). The differentiated B cell ble of interaction with PU.1, DNA binding, and activation
line A20 was used as a positive control that already of gene expression (IgLl) to a conformation that no
expressed high amounts of IgLl (Figure 6, upper panel, longer interacts with PU.1 or binds DNA. Ascomycin
lane 1). Inhibition of PPIase activity also increased IgLl relieves the inhibition catalyzed by FKBP52 by abrogat-
expression in these cells by 4-fold (Figure 6, upper panel, ing the PPIase activity of the immunophilin.
lane 2), whereas no such increase was detected in Jurkat The inhibition of IRF-4-PU.1 DNA binding and trans-
T cells treated with the drug (Figure 6, upper panel, lane activation potential by FKBP52 has important implica-
9). Finally, ascomycin had no effect on GAPDH or IRF-4 tions for B cell development. The IRF-4-PU.1 complex
mRNA expression levels (Figure 6, middle and bottom is essential for the expression of the IgLl and the J
panels). chain genes. Both genes are required for the expression
of a productively rearranged immunoglobulin l gene in
plasma cells (Brass et al., 1999). FKBP52 may thereforeDiscussion
function as a negative regulator of immunoglobulin gene
expression during B cell differentiation, or alternativelyIn the present study, a novel interaction between IRF-4
and the immunophilin FKBP52 has been characterized. it may act to prevent expression of certain genes prior
to the plasma cell stage. Inhibition of the transactivatingThe proline-rich region of IRF-4 (aa 150±237) and the
C-terminal tetratricopeptide repeats of FKBP52 were the complex IRF-4-PU.1 by FKBP52 suggests a new role
for immunophilins in the regulation of B cell developmentminimal domains required for interaction. Association of
FKBP52 with IRF-4 inhibited IRF-4-PU.1 binding to the and maturation.
Previously, the IRF-4-PU.1 dimer was shown to stimu-IgLl enhancer El2±4, as well as IRF-4 interaction with the
ISG-15 ISRE element. Furthermore, inhibition of IRF-4 late the transcriptional activity of the El2±4 lB element
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Figure 7. Schematic Model of the Role of
FKBP52 in Regulating IRF-4 Function
(A) PPIase catalyzes cis-trans isomerization
at specific proline residues. Peptide bonds on
the amino side of proline residues are found
mainly in the trans-conformation. The ap-
pearance of the cis-conformation is catalyzed
by PPIase (upper panel). Amino acid preced-
ing (A21) and following the proline residue (A2)
are linked to polypeptide chains (adapted
from Kay, 1996). Residues within the proline-
rich domain of IRF-4 (aa 150±237) that may
be subject to isomerization by FKBP52 are
underlined (lower panel).
(B) Schematic model describing the potential
functions of FKBP52 in mediating nuclear
transport/chaperone function, protein folding
by cis-trans isomerization, and regulation of
IRF-4 functions such as DNA binding and
transactivation. DBD, DNA-binding domain;
IAD, IRF-association Domain; Pro, proline-
rich region; closed diamond, tetratricopep-
tide repeats.
in a synergistic manner (Eisenbeis et al., 1995; Brass et autoinhibition of DNA binding and ternary complex for-
mation (Brass et al., 1996). Consistent with these ob-al., 1996). A model of IRF-4-PU.1 complex activation
proposed that in the absence of PU.1, IRF-4 was in a servations, FKBP52 did not immunoprecipitate with
full-length IRF-4; only after removal of the C-terminalclosed conformation unable to bind to the El2±4 lB ele-
ment. Following interaction of IRF-4 with PU.1 and DNA, autoinhibition domain (aa 411±450) did IRF-4 interact
with FKBP52. IRF-4 appears to be modified by FKBP52IRF-4 underwent a conformational change that swiveled
the regulatory domain (aa 170±450) away from its own through proline isomerization to maintain a closed non±
DNA binding conformation, which is relieved throughDBD (aa 1±150) and into direct contact with the PEST
region of PU.1. Furthermore, deletion of the C-terminal the intermolecular interaction with PU.1. As described
previously (Eisenbeis et al., 1995; Brass et al., 1996,segment generated a form of IRF-4 with PU.1-indepen-
dent binding activity (Brass et al., 1996, 1999). Ortiz 1999), IRF-4 may be inaccessible to FKBP52 because
of structural constraints imposed by the C-terminal au-et al. further delimited the IRF-4 interaction domain to
residues 245±422 (Ortiz et al., 1999). Site-directed muta- toinhibition element.
Several physiological roles have been ascribed to im-genesis of conserved amino acids within two predicted
a helices confirmed the importance of these residues munophilins: (1) binding and sequestration of cal-
cineurin, (2) protein folding and assembly, (3) proteinfor IRF-4-PU.1 DNA binding and transactivation. These
two a helices are also highly conserved amongst the trafficking, (4) direct regulation of protein activity, and
5) chaperone-like activity (Kay, 1996). Immunophilins areIRF family members and could therefore be involved in
heterodimerization with other transcription factors (Ortiz peptidyl-prolyl isomerases (PPIases) involved in catalyz-
ing cis-trans isomerization of proline residues withinet al., 1999). To analyze the function of the IRF-4-PU.1
dimer in vivo, a chimeric repressor was engineered by proteins. cis prolines are important to protein structural
integrity because they introduce bends within proteins.fusing PU.1 and IRF-4 DNA-binding domains through a
flexible POU domain. This fused dimer strongly re- During protein synthesis, the peptide bonds on the
amino side of proline residues are found in the openpressed expression of a rearranged immunoglobulin
gene (IgLl) (Brass et al., 1999). trans-conformation (Figure 7A). When the three-dimen-
sional structure was determined, 15% of these bondsDeletion analysis of IRF-4 also revealed the presence
of a C-terminal segment (aa 410±450) important for were in the alternate cis-conformation (Kay, 1996;
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Marks, 1996). Enzymes with peptidyl-prolyl isomerase observed at 4±5 weeks of age, but with time IRF-42/2
activity such as FKBP52 catalyze the cis-trans intercon- mice gradually exhibited severe lymphadenopathy and
version, a modification that would otherwise occur defects in both B and T cell activation (MittruÈ cker et al.,
slowly. Immunophilins target specific proline residues 1997). Early T cell events such as calcium influx and
preceded by a bulky hydrophobic residue for cis-trans expression of the T cell activation markers CD25 and
isomerization (Kay, 1996; Marks, 1996; Hunter, 1998). CD69 remained normal in IRF-42/2 T cells, indicating that
Within IRF-4, several clustered prolines preceded by IRF-4 may function at later stages of T cell activation,
hydrophobic residues are available for peptidyl-prolyl possibly at the level of IL-2 production and/or IL-2 re-
isomerization by FKBP52 (Figure 7A). In the model illus- sponse. The unexpected convergence of transcription
trated in Figure 7B, we propose that FKBP52 can act factors and immunophilins suggests a novel posttrans-
as a chaperone that escorts IRF-4 into the nucleus. lational role for immunophilins in the regulation of gene
During transport or once in the nucleus, FKBP52 would transcription and cell growth in lymphocytes.
alter IRF-4 conformation through proline isomerization,
thereby sequestering IRF-4. The interaction with the Experimental Procedures
proper transcriptional partner such as PU.1 would allevi-
Yeast Two-Hybrid Screenate this inhibitory effect and permit DNA binding and
The fragment containing the proline-rich and IRF association do-transactivation of target genes such as IgLl (Figure 7B).
mains (aa 150±410) of IRF-4 was PCR amplified with primer AOne of the first members of the immunophilin family,
(59-ATCAGAATTCCCGGGAGTGTACAGGATTGTTCC-39) and primer B
cyclophilin A, was shown to be the primary target of (59-ATCAGTCGACGGATCCTGAGGGTCTGGAAACTCC-39) and sub-
cyclosporin A, a clinically used immunosuppressive cloned into the pAS2-1 vector (GAL4 1±147 DNA-binding domain,
drug that blocks the calcineurin-dependent activation TRP1; Clontech) in frame with the DNA-binding domain of GAL4
and sequenced. The yeast strain was cotransformed by the lithiumof NF-AT in T cells (Emmel et al., 1989; Mattila et al.,
acetate permeabilization method with the pAS2-1-IRF-4 (150±410)1990; Morris, 1994; Mattila, 1996). FKBP52 (HBI, p59,
vector and with an EBV-transformed B cell cDNA library cloned intoHSP56) was originally discovered in association with
the pACT vector (Clontech). Positive yeast clones were selected for
unliganded steroid receptor complexed with heat shock prototrophy for leucine, tryptophan, and histidine and screened for
proteins HSP70 and HSP90 and involved in cytoplasmic- b-galactosidase expression. Subsequent two-hybrid assays were
to-nuclear shuttling (Peattie et al., 1992; Perrot-Applanat carried out by a mating assay between the Y187 and Y190. Diploid
cells from the mating assay were selected for Trp-, Leu-, and His-et al., 1995). Recently, another member of the immu-
selective medium and screened by replica plating for their ability tonophilin family, the human cyclophilin Cyp-40, was
produce for b-galactosidase. Plasmid DNA was isolated from yeastshown to regulate the transcriptional activity of c-Myb
and transformed in E. coli DH5a by electroporation. The constructstranscription factor (Gonda, 1998; Gonda et al., 1989)
were sequenced using 59PACT primer (59-TACCACTACAATGGATG-39).
by interfering with the capacity of c-Myb to bind DNA;
interestingly, the oncogenic form of v-Myb evaded this Protein Expression and Purification
inhibition of DNA binding (Leverson and Ness, 1998). The GST-FKBP52 fusion protein was expressed and isolated from
Point mutations and deletions in v-Myb that contribute E. coli BL21 following a 3 hr induction with 1 mM IPTG (Pharmacia)
at 308C. Bacterial extracts in PBS containing 1% Triton X-100 wereto its oncogenic potential also abrogate the cyclophilin-
incubated with glutathione Sepharose beads (Pharmacia) for 20 minmediated inhibition of DNA binding of v-Myb (Lipsick,
at room temperature and the fusion protein was eluted as previously1996; Gonda, 1998). By analogy with c-Myb and Cyp-
described (Lin et al., 1999) The batches were 80%±90% pure with
40, IRF-4 interacts with an immunophilin that inhibits its a concentration of 33±100 ng/ml. The IRF-4 fusion protein was ex-
DNA binding activity and transactivation potential in a pressed as a poly-histidine tagged protein, isolated from E. coli
PPIase-dependent fashion. BL21 following a 3 hr induction with 1 mM IPTG (Pharmacia) at 308C.
One of the original sources of IRF-4 was adult T cell Bacterial extracts in PBS containing 1% Triton X-100 were incubated
with His-Bind resin (Novagen) for 20 min at room temperature. Highleukemia cell lines (Yamagata et al., 1996). The specific
purity (95%) and concentration (100 ng/ml) were obtained.detection of high levels of IRF-4 expression in HTLV-1-
infected cells was unexpected, since IRF-4 expression
CAT Assay, Western Blot Analysis, and Coimmunoprecipitationin activated T cells was often difficult to detect (Yama-
The HTLV-1-infected cell lines C8166, MT-2, MT-4, and Jurkat Tgata et al., 1996). Interestingly, HTLV-1 Tax expression cells were cultured in RPMI 1640 media (CLT), the MO-T cell line in
appears to correlate with IRF-4 expression and may be Iscove's media (CLT) supplemented with 10% fetal bovine serum,
acting in an indirect manner to stimulate gene expres- and antibiotics. The B cell lines were purchased from ATCC and
sion through the interaction with host transcription cultured according to their directives. The A20 cell line was cultured
in RPMI 1640/10% fetal bovine serum to express high amounts offactors (Hiscott et al., 1995). The role of IRF-4 per se
surface immunoglobulins (ATCC). All CAT assays and coimmuno-in HTLV-1-induced leukemogenesis remains unclear.
precipitations were carried in monkey embryonic kidney COS-7 cellsHowever, the relationship between IRF-4 expression
grown in Dulbecco's MEM media (GIBCO±BRL) supplemented with
and oncogenicity is highlighted by the observation that 10% fetal bovine serum and antibiotics. Subconfluent cells were
in some patients with multiple myeloma, a chromosomal transfected with 2±15 mg of CsCl purified plasmid by lipofectamine
translocationÐt(6;14)(p25;q32)Ðjuxtaposes the immu- (CLT) method. The reporter plasmids contained the IRF-4-PU.1-
noglobulin heavy chain (IgH) locus to MUM1 (multiple responsive elements (B4TK-CAT) (Eisenbeis et al., 1995) or the inter-
feron-stimulated gene 15 (ISG15) promoter (Lin et al., 1998) linkedmyeloma 1); the MUM1 locus at 6p25 is virtually identical
to the CAT reporter gene as well as the IRF-4-, PU.1-, DN-FKBP52-to IRF-4. This chromosomal translocation involving IRF-4
(aa 233±459), and FKBP52-expressing plasmids. Sixteen hoursmay thus contribute to leukemogenesis, since MUM1/
post-transfection, transfected COS-7 cells were treated with asco-
IRF-4 has oncogenic activity in vitro (Iida et al., 1997). mycin (2 mM) or DMSO. At 48 hr after the transfection, total protein
A potential candidate gene that may be modulated in extracts were prepared and 10 mg were used for CAT assay. CAT
HTLV-1-infected cells by IRF-4 is the IL-2 gene. In IRF- activities represent an average of CAT values obtained from three to
six independent experiments. For Western blot analysis, equivalent4-deficient mice, a normal T and B cell distribution was
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